New Compound TOFA Increases Energy Use and Reduces Fat Without Muscle Loss in Mice
In recent years, GLP-1 medications have significantly changed the landscape of obesity and diabetes treatment, with drugs like Ozempic, Wegovy, Mounjaro, and Zepbound demonstrating the ability to promote substantial weight loss while aiding in blood sugar control. However, these medications can lead to side effects such as nausea and gastrointestinal discomfort, and their appetite-suppressing nature may contribute to nutritional deficiencies and muscle loss, raising concerns about long-term health risks.
Researchers at the University of California, Berkeley, are exploring an alternative strategy for treating obesity and diabetes that focuses on increasing the body's energy expenditure rather than merely reducing caloric intake. In a study published on August 21 in Science Advances, the team investigated a molecular compound known as 5-tetradecyloxy-2-furoic acid (TOFA). This compound has the potential to disrupt lipid production while simultaneously activating genes that promote fat utilization for energy.
In experiments conducted on mice, TOFA was found to enhance insulin sensitivity and glucose regulation, lower triglyceride levels, and alleviate symptoms of fatty liver disease. Notably, the obese mice treated with TOFA experienced fat loss without a significant decrease in lean muscle mass. Anders Näär, a professor of metabolic biology and nutrition at UC Berkeley and the study's senior author, emphasized the dual approach to body weight management: reducing caloric intake or increasing energy expenditure. While GLP-1 medications primarily target the former, the research team aimed to enhance the latter.
Originally discovered in the 1970s, TOFA belongs to a class of compounds called ACC inhibitors, which are known to decrease lipid production. Although several ACC inhibitors have progressed to mid-stage clinical trials, none have been approved for treating metabolic diseases due to concerns that they may elevate triglyceride levels, thus increasing cardiovascular risk. However, the UC Berkeley researchers observed that TOFA does not exhibit this adverse effect, likely due to its unique ability to activate PPARα and PPARδ, receptors that regulate fat uptake and energy expenditure.
The study revealed that TOFA could boost energy use by as much as 18% in mice without necessitating increased physical activity or elevated body temperature. The researchers noted that TOFA's mechanism appears to engage a coordinated metabolic response, enhancing energy expenditure pathways alongside lipid synthesis inhibition.
In an effort to assess the effectiveness of TOFA compared to a combination of two separate compounds—one designed to suppress lipid production and the other to increase energy expenditure—the researchers found that TOFA alone outperformed the dual approach in improving overall metabolic health. Furthermore, when TOFA was combined with existing GLP-1 medications, the results showed greater improvements in body weight, glucose control, insulin levels, and triglycerides than either treatment alone.
Despite these promising findings, the researchers caution that TOFA has only been tested in animal models, and its safety and efficacy in humans remain to be determined. To advance this research toward potential clinical applications, the team has established a company called ReRx Therapeutics, supported by Berkeley's life sciences entrepreneurship ecosystem, including Nucleate and Berkeley SkyDeck. The study received funding from UC Berkeley's discretionary funds, with additional support from the UCSF Liver Center and the University of Michigan Animal Phenotyping Core. The research team included several contributors from various institutions, highlighting the collaborative effort in this significant area of study.




